Category: Pharmaceuticals
Pharmaceuticals market research reports by Inkwood Research
-
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ZILOSUL, also known as pentosan polysulfate sodium (PPS), is a semi-synthetic medication derived from the wood chips of European beech trees. The extraction process yields glucurono-xylans, which are then sulfated to crea ... Read More
-
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 X0002, also known as ibuprofenamine hydrochloride spray, is an innovative transdermal non-steroidal anti-inflammatory drug (NSAID) currently under clinical development for the treatment of osteoarthritis (OA) and rheumatoid ... Read More
-
Japan Dry Eye Disease Market Forecast 2024-2032
Japan Dry Eye Disease Market Forecast 2024-2032 The Japan dry eye disease market is projected to grow at a CAGR of 5.26% from 2024 to 2032. The market was valued at $251.44 million in 2023, reaching an expected revenue of $401.68 million by 2032. The rising prevalence of dry eye diseases in Japan is ... Read More
-
Asia-pacific Dry Eye Disease Market Forecast (2024-2032)
Asia-pacific Dry Eye Disease Market Forecast (2024-2032) The Asia-Pacific dry eye disease market is projected to grow at a CAGR of 5.51% during the forecast period from 2024 to 2032. The market was valued at $1216.91 million in 2023, reaching a revenue of $1987.33 million by 2032. MARKET INSIGHTS Fa ... Read More
-
Global Dry Eye Disease Market Forecast 2024-2032
Global Dry Eye Disease Market Forecast 2024-2032 As per Inkwood Research, the global dry eye disease market is expected to grow at a CAGR of 5.02% during the period from 2024 to 2032. The market was valued at $5673.53 million in 2023, reaching a revenue of $8884.34 million by 2032. Dry eye disease i ... Read More
-
Europe Dry Eye Disease Market Forecast 2024-2032
Europe Dry Eye Disease Market Forecast 2024-2032 The Europe dry eye disease market is projected to grow at a CAGR of 4.70% during the forecast period from 2024 to 2032. The market was valued at $1686.02 million in 2023, reaching a revenue of $2569.11 million by 2032. MARKET INSIGHTS The Europe dry e ... Read More
-
China Dry Eye Disease Market Forecast 2024-2032
China Dry Eye Disease Market Forecast 2024-2032 The China dry eye disease market is expected to grow at a CAGR of 5.81% from 2024 to 2032. The market was valued at $384.43 million in 2023, with projected revenue reaching $643.91 million by 2032. The market’s expansion is driven by a combination of f ... Read More
-
North America Dry Eye Disease Market Forecast 2024-2032
North America Dry Eye Disease Market Forecast 2024-2032 The North America dry eye disease market is expected to grow at a CAGR of 5.12% during the forecast period of 2024 to 2032. The market was valued at $2283.72 million in 2032, reaching a projected revenue of $3604.57 million by 2032. MARKET INSI ... Read More
-
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 WEGOVY (Semaglutide) is a synthetic version of the human glucagon-like peptide-1 (GLP-1) hormone. It promotes weight loss by decreasing appetite, enhancing feelings of fullness, reducing food consumption, and lowering calo ... Read More
-
United States Dry Eye Disease Market Forecast 2024-2032
United States Dry Eye Disease Market Forecast 2024-2032 The United States dry eye disease market is projected to grow at a CAGR of 5.09% from 2024 to 2032. The market was valued at $2103.11 by 2023, reaching a revenue of $3313.01 million by 2032. One of the primary drivers furling the country’s mark ... Read More
-
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 TLC599 is a proprietary formulation of dexamethasone sodium phosphate (DSP) utilizing the BioSeizer technology, designed to deliver up to 24 weeks of continuous pain relief. TLC599 offers the benefit of locally delivering ... Read More
-
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 Sprifermin (AS-902330) is a recombinant version of human fibroblast growth factor 18 (FGF18). Sprifermin acts as a strong agonist for FGFR2 and FGFR3 receptors. It is administered through injections directly into the j ... Read More
-
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 RTX-GRT7039 (resiniferatoxin) is an investigational drug designed for pain relief in patients with knee osteoarthritis (OA). This highly potent agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor ... Read More
-
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ReNu is a cryopreserved amniotic suspension allograft (ASA) containing micronized amniotic membrane and amniotic fluid cells. The amniotic membrane serves a protective function, surrounding the fetus and acting as a barrier ... Read More
-
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 MM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. This treatment utilizes the unique characteristics of proprietary multilamellar liposomes alongside an inn ... Read More
-
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 Lorecivivint (SM04690) is a small-molecule inhibitor targeting the Wnt pathway, delivered through intra-articular injection, and is being explored as a potential disease-modifying osteoarthritis drug (DMOAD). Preclin ... Read More
-
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 LNA043 is an innovative ANGPTL3 (angiopoietin-like 3) agonist designed to specifically target and repair damaged cartilage while influencing multiple pathways involved in cartilage regeneration. This drug is being explored ... Read More
-
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 JTA-004 is an innovative treatment in development for managing knee osteoarthritis pain through intra-articular injections. This advanced osteoarthritis (OA) medicine features a proprietary blend of hyaluronic acid and pl ... Read More
-
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 INVOSSA is a groundbreaking cell and gene therapy designed to treat knee osteoarthritis with a single intra-articular injection. Clinical trials conducted in the United States and globally have demonstrated that INVOSSA c ... Read More
-
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 ELIXCYTE is an allogeneic stem cell product derived from adipose tissue, designed to regulate the immune system, reduce inflammation, and promote chondrocyte proliferation while supporting the normal function of damaged ... Read More
-
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 CNTX-4975 is currently being evaluated as a treatment for moderate to severe knee osteoarthritis (OA) pain. It is a highly purified, synthetic form of trans-capsaicin administered via injection directly to the pain site ... Read More
-
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Upto 2032 AMZ001 is a new topical gel formulation of diclofenac, developed specifically to treat knee osteoarthritis (OA) pain. With a high-strength concentration of 3.06% diclofenac sodium, AMZ001 stands out in the osteoarthritis m ... Read More
-
Pre-eclampsia - Early-stage Therapy - Pipeline Insight 2024
Pre-eclampsia - Early-stage Therapy - Pipeline Insight 2024 Pre-eclampsia is a common pregnancy-related complication, affecting 2–15% of pregnancies, and poses serious risks to both mother and fetus. This pregnancy complication usually develops after 20 weeks of gestation and is characterized by hig ... Read More
-
Dry Age Macular Degeneration (Dry Amd) - Early-stage Therapy - Pipeline Insight 2024
Dry Age Macular Degeneration (Dry Amd) - Early-stage Therapy - Pipeline Insight 2024 Age-related macular degeneration (AMD) is a progressive eye disease primarily affecting individuals over the age of 50, particularly within the highly geriatric population, leading to the deterioration of the macula ... Read More
-
Japan Cancer Pain Management Market Forecast 2024-2032
Japan Cancer Pain Management Market Forecast 2024-2032 The Japan cancer pain management market is expected to grow with a CAGR of 5.75% during the forecast period 2024-2032. MARKET INSIGHTS According to the National Institutes of Health study, Cancer Prevalence Projections in Japan and Decomposition ... Read More
Research Assistance
